Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235. European journal of nuclear medicine and molecular imaging Bazan, J. G., Duan, F., Snyder, B. S., Horng, D., Graves, E. E., Siegel, B. A., Machtay, M., Loo, B. W. 2016: -?

Abstract

To determine whether higher pre-treatment metabolic tumor volume (tMTV-pre) is associated with worse overall survival (OS) in patients with inoperable NSCLC treated with definitive chemoradiation (CRT).This is a secondary analysis of the American College of Radiology Imaging Network (ACRIN) 6668/Radiation Therapy Oncology Group 0235 trial. Pre-treatment PET scans were performed on ACRIN-qualified scanners. Computer-aided MTV measurement was performed using RT_Image. Kaplan-Meier curves and Cox proportional hazards regression models were used to assess the association between tMTV and OS.Of the 250 patients enrolled on the study, 230 were evaluable for tMTV-pre. Patients with MTV-pre >32 mL (median value) vs. =32 mL had worse median OS (14.8 vs. 29.7 months, p? 32 mL who received =60 Gy compared with those who received 61-69 Gy or =70 Gy (p?=?0.001).Higher tMTV-pre is associated with significantly worse OS in inoperable stage III NSCLC treated with definitive CRT. Our findings suggest that for patients with large tMTV-pre, achieving a therapeutic radiation dose may help maximize OS. Prospective studies are needed to confirm this finding.

View details for PubMedID 27645692

View details for PubMedCentralID PMC5121029